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Background: Lipodystrophies are characterized by adipose tissue redistribution, insulin resistance (IR) and
metabolic complications. Adipokines and hormones related to body composition may play an important role
linking these alterations. Our aim was to evaluate adipocyte-derived hormones (adiponectin, leptin, resistin, TNF-α,
PAI-1) and ghrelin plasma levels and their relationship with IR in HIV-infected patients according to the presence of
lipodystrophy and fat redistribution.
Methods: Anthropometric and metabolic parameters, HOMA-IR, body composition by DXA and CT, and adipokines
were evaluated in 217 HIV-infected patients on cART and 74 controls. Fat mass ratio defined lipodystrophy (L-FMR)
was defined as the ratio of the percentage of the trunk fat mass to the percentage of the lower limb fat mass by
DXA. Patient’s fat redistribution was classified into 4 different groups according the presence or absence of either
clinical lipoatrophy or abdominal prominence: no lipodystrophy, isolated central fat accumulation (ICFA), isolated
lipoatrophy and mixed forms (MXF). The associations between adipokines levels and anthropometric, metabolic and
body composition were estimated by Spearman correlation.
Results: Leptin levels were lower in patients with FMR-L and isolated lipoatrophy, and higher in those with ICFA
and MXF. Positive correlations were found between leptin and body fat (total, trunk, leg, arm fat evaluated by DXA,
and total, visceral (VAT), subcutaneous adipose tissue (SAT), and VAT/SAT ratio evaluated by CT) regardless of FMR-L,
and with HOMA-IR only in patients with FMR-L. Adiponectin correlated negatively with VAT, and its mean levels
were lower in patients with ICFA and higher in those with no lipodystrophy. Resistin was not correlated with
adipose tissue but positively correlated with HOMA-IR in FMR-L patients. PAI-1 levels were higher in MXF-patients
and their levels were positively correlated with VAT in those with FMR-L. Ghrelin was higher in HIV-infected patients
than controls despite BMI-matching.
Conclusion: The overall body fat reduction in HIV lipoatrophy was associated with low leptin plasma levels, and
visceral fat accumulation was mainly associated with decreased plasma levels of adiponectin.
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Changes in body fat distribution are a common finding in
HIV infected patients treated with combined antiretroviral
therapy (cART) and this condition has many similarities
to rare, congenital and acquired lipodystrophies, which are
associated with depletion of subcutaneous fat, increased
triglycerides and profound insulin resistance (IR) [1,2].
Adipose tissue traditionally was considered an energy
storage organ, but over the last decade, it has emerged as
a metabolically active endocrine organ secreting multiple
bioactive peptides, collectively called “adipokines”, other
proteins including inflammatory mediators such as tumor
necrosis factor alpha (TNF-α) and plasminogen activator
inhibitor-1 (PAI-1), which not only influence adipocyte
function in an autocrine and paracrine fashion, but also
affect more than one metabolic pathway through the
bloodstream’s systemic circulation [3]. All adipose tissue
products seem to contribute significantly in various meta-
bolic processes both at local and systemic levels and may
induce proinflammatory state and oxidative damage, lead-
ing to initiation and progression of atherosclerosis [4]. On
the other hand, these patients experience marked changes
in circulating levels of adipocyte secreted hormones, in-
cluding leptin and adiponectin, contributing to metabolic
abnormalities, and hormones related to body composition,
such as ghrelin [5]. Ghrelin is an orexigenic gut peptide
that is the endogenous ligand for the growth hormone
(GH) secretagogue receptor. Low ghrelin may be a marker
of metabolic dysregulation and altered body fat without
specifically contributing to low GH [6].
cART in HIV infection produces widespread metabolic
complications, including hyperlipidemia, IR and lipo-
dystrophy [peripheral fat wasting (lipoatrophy) with or
without abdominal/visceral fat accumulation (lipohyper-
trophy)] [7]. The hormonal changes caused by increased
(in lipohypertrophy) or reduced subcutaneous fat (in
lipoatrophy) may be central to the metabolic abnor-
malities observed in HIV-lipodystrophy [6].
The aim of this study was to evaluate the relationship
between fat mass, lipodystrophy defined by the Fat Mass
Ratio (FMR-L) and the four different categories of fat dis-
tribution, and adipocyte derived hormones (adiponectin,
leptin, resistin, TNF-α), orexigenic hormones (ghrelin),
prothrombotic factors (PAI-1) and IR in HIV-infected pa-
tients on cART.
Methods
Subjects
As part of a cross-sectional study, 217 consecutive cli-
nically stable HIV-infected adults receiving cART were
evaluated between 2005 and 2008 at the Endocrinology
Outpatient Department. Seventy four age-, gender- and
BMI-matched HIV-uninfected controls were also eva-
luated. These controls were selected from a previouslyassembled cohort of non-institutionalized community
adults, the EPI-Porto study [8]. This study was approved
by the Ethics Committee for Health of Hospital São João
and each patient provided written informed consent.Clinical assessment
For each patient the following information was collected
using a standardized protocol: demographic data (age,
gender), duration of HIV infection, HIV infection risk
factors, duration of cART and characterization of the in-
fection. We used the “Centers for Disease Control and
Prevention” (CDC) criteria for classifying the degree the
infection [9]. Weight, height, circumferences of neck,
waist, hip, thigh and arm were measured as previously
published [10-13]. Blood pressure (BP) was measured
using the established recommendations [14].
Clinical lipodystrophy was defined as a peripheral lipoa-
trophy with or without a central fat accumulation assessed
by both patient and practitioner, as previously described
[11-13]. Presence of central fat accumulation or abdom-
inal prominence was defined by the measurement of waist
circumference using the International Diabetes Federation
(IDF) criteria for metabolic syndrome [15]. Patients were
classified into four different categories according the pre-
sence or absence of either clinical lipoatrophy or abdo-
minal prominence: no lipodystrophy - patients without
clinical lipoatrophy and without abdominal prominence;
isolated central fat accumulation - patients without
clinical lipoatrophy and with abdominal prominence;
isolated lipoatrophy - patients with clinical lipoatrophy
and without abdominal prominence; mixed forms of
lipodystrophy - patients with clinical lipoatrophy and
with abdominal prominence. The clinical assessment was
performed by the same practitioner (PF).Evaluation of body composition
Body composition was assessed with whole-body dual-
energy X-ray absorptiometry (DXA – Lunar Expert XL).
DXA measurement was performed while the patient was
in a supine position, with standard positioning of the arms
and feet. Markers used in this study for trunk and lower
limbs that defined regions of interest as indicated by the
manufacturer. Regional fat mass values were grouped and
analysed for the following anatomical regions: arms, legs,
trunk and total body. The fat mass ratio (FMR) is the ratio
of the percentage of the trunk fat mass to the percentage of
the lower limb fat mass (FMR= % of the trunk fat mass/%
of the lower limb fat mass) [16]. We define lipodystrophy
by FMR using the cut-off value of 1.961 for men and 1.329
for women [10]. The quantification of total, visceral, and
peripheral abdominal fat was performed with a 64-slice
computed tomography (CT) scanner (Siemens Sensation
64 Cardiac) with the same technique as previously
Freitas et al. BMC Infectious Diseases 2014, 14:347 Page 3 of 13
http://www.biomedcentral.com/1471-2334/14/347described [17,18]. All values were expressed in cm2
rounded to the nearest centesimal.
Laboratory analysis
A venous blood sample was drawn after a 12-hour over-
night fast. All the samples were analysed at the central
laboratory of our hospital. Patients without a previous
diagnosis of diabetes were submitted to a glucose tole-
rance test (OGTT). The test was performed as described
by the World Health Organization using a glucose load
containing the equivalent of 75 g anhydrous glucose dis-
solved in water.
The CD4 cell count was determined by flow cytometry
and plasma HIV-1 RNA loads were measured by a quan-
titative reverse transcriptase polymerase chain reaction
(Roche Diagnostic Systems, Inc., Branchburg, NJ, USA),
which has a lower limit of detection of 50 copies/mL.
Adipokines and hormones related to body composition
Leptin (Human Leptin RIA Kit, Linco Research), adipo-
nectin (Human Adiponectin RIA Kit, Linco Research),
resistin (Human Resistin ELISA Kit, Linco Research),
TNF-α (TNF-α IRMA Kit, BioSource), ghrelin (Ghrelin
Active RIA Kit, Linco Research) and PAI-1 (Human
PAI-1 ELISA Kit, IBL International GMBH) were mea-
sured in the Nobre Laboratory of the Porto Medical
School. For leptin, the intra-assay precision is 4.6% and
inter-assay precision 5.0%. For adiponectin, the intra-
assay precision is 1.8% and inter-assay precision 9.3%.
For resistin, the intra-assay precision is 3.2% and inter-
assay precision 7.1%. For TNF-α, the intra-assay preci-
sion is 3.1% and inter-assay precision 5.7%. For ghrelin,
the intra-assay precision is 6.7% and inter-assay preci-
sion 9.6%. The overall intra-assay coefficient of variation
for PAI-1 was 4.7%.
Insulin resistance evaluation
Insulin resistance was defined by the homeostasis model
assessment of insulin resistance (HOMA) and insulin sen-
sitivity by the quantitative insulin sensitivity check index
(QUICKI). These indexes were calculated by the following
formulas:
HOMA-IR index = (insulin 0 × glucose 0)/22.5 [19].
QUICKI = 1/[log (fasting insulin in mU/l) + log (fasting
plasma glucose in mg/dL)] [20].
Glucose was expressed in mmol/L and insulin in μUI/mL.
Statistical analysis
Data were described as mean and standard deviation
(SD) for quantitative variables and compared using the
Student-t test or the Mann–Whitney test as appropriate.
For the comparison between the four groups of fat dis-
tribution and adipokines parameters the Kruskall-Wallis
test was used. Categorical variables were described ascounts and proportions, and compared using the chi-
square or Fisher’s exact test.
For estimating the association between adipokines levels
and anthropometric, metabolic and body composition,
Spearman correlation coefficients were calculated. Statis-
tical analysis was performed using the SPSS version 18.0
software (SPSS Inc., Chicago, Illinois, USA). All proba-
bilities were two tailed and p values <0.05 were regarded
as significant, with the exception of the correlations bet-
ween adipokines levels and anthropometric, metabolic
and body composition, considering p values <0.001 as sig-
nificant after applying the Bonferroni correction.
Results
Sample characteristics, adipokines and hormones related
to body composition in HIV-infected patients and
HIV-uninfected controls
HIV-infected patients had significantly higher waist/hip
ratio, glucose, triglyceride, insulin, HOMA, and ghrelin
levels, and adiponectin/leptin ratio. However, they had
lower weight, hip and arm circumferences, HDL-choles-
terol levels, QUICKI, resistin, adiponectin and leptin levels.
No differences were observed between HIV-infected pa-
tients and HIV-uninfected controls regarding waist cir-
cumference, systolic and diastolic blood pressure and total
cholesterol, LDL-cholesterol, uric acid, hsCRP and TNF-α
levels (Table 1).
Adipokines and hormones related to body composition in
HIV-infected patients according to gender
HIV-infected females had higher hip circumference, total
fat mass and subcutaneous adipose tissue (SAT) on
abdominal CT scan evaluation and total, trunk, leg and
arm mass fat by DXA. They also had lower visceral adi-
pose tissue (VAT) and VAT/SAT ratio on CT scan. Also,
females had higher leptin levels and lower TNF-α and
adiponectin/leptin ratio. No gender-related differences
were observed in adiponectin, resistin, ghrelin and PAI-1
levels (Table 2).
Adipokines and hormones related to body composition
according to the four categories of body composition
Patients with isolated central fat accumulation and mixed
forms of lipodystrophy were older and had higher BMI.
Patients with no lipodystrophy had higher levels of adipo-
nectin and those with isolated central fat accumulation
had the lowest levels of adiponectin. The levels of leptin
were higher in patients with isolated central fat accumula-
tion and mixed forms of lipodystrophy and lower in those
with isolated lipoatrophy. No significant differences were
observed in resistin, ghrelin and TNF-α levels between the
four groups of body composition. Patients with no lipody-
strophy and mixed forms of lipodystrophy had higher
levels of PAI-1, and the lowest levels of PAI-1 were
Table 1 Sample characteristics, adipokines and hormones related to body composition in HIV-uninfected controls and
HIV-infected patients
HIV-uninfected controls HIV-infected patients p
n 74 217
Age [years, mean (sd)] 47.2 (9.7) 46.6 (11.6) 0.73
Gender [n (%)]
Male 40 (54.1) 144 (66.9)
Female 34 (45.9) 73 (33.6) 0.08
Weight [Kg, mean (sd)] 71.5 (13.4) 67.8 (12.3) 0.03
BMI [(kg/m2), mean (sd)] 26.3 (4.3) 35.1 (4.5) 0.05
Waist circumference [cm, mean (sd)] 90.7 (11.6) 91.2 (11.6) 0.75
Hip circumference [cm, mean (sd)] 99.8. (7.1) 94.5 (8.4) <0.001
Waist/hip ratio [mean (sd)] 0.91 (0.08) 0.96 (0.08) <0.001
Arm circumference [cm, mean (sd)] 30.6 (3.5) 27.0 (3.0) <0.001
Systolic blood pressure [mmHg, mean (sd)] 122.2 (17.3) 121.9 (17.5) 0.99
Diastolic blood pressure [mmHg, mean (sd)] 78.9 (10.1) 76.7 (11.3) 0.24
Glucose [mg/dL, mean (sd)] 91.7 (12.2) 107.7 (41.5) 0.03
Insulin [μU/mL, mean (sd)] 5.5 (4.9) 11.2 (10.6) <0.001
HOMA [mean (sd)] 1.3 (1.4) 3.1 (3.2) <0.001
QUICKI [mean (sd)] 0.39 (0.05) 0.36 (0.08) <0.001
Total cholesterol [mg/dL, mean (sd)] 217.2 (43.6) 224.2 (58.0) 0.26
LDL cholesterol [mg/dL, mean (sd)] 134.9 (38.8) 128.5 (49.9) 0.42
HDL cholesterol [mg/dL, mean (sd)] 57.4 (14.9) 46.1 (13.6) <0.001
Triglycerides [mg/dL, mean (sd)] 119.8 (57.6) 267.5 (182.8) <0.001
Uric acid [mg/dL, mean (sd)] 49.6 (15.4) 46.8 (15.0) 0.165
hs-CRP [mg/dL, mean (sd)] 0.36 (0.54) 0.45 (0.73) 0.55
Resistin [ng/mL, mean (sd)] 15.5 (11.0-22.2) 10.4 (8.0-13.9) <0.001
Adiponectin [μg/mL, mean (sd)] 5.18 (2.80-7.74) 2.68 (1.19-5.46) <0.001
TNF-α [pg/mL, mean (sd)] 45.3 (29.9-60.5) 44.6 (30.1-73.6) 0.63
Ghrelin [pg/mL, mean (sd)] 18.6 (10.5-25.4) 75.0 (47.7-139.5) <0.001
Leptin [ng/mL, mean (sd)] 11.8 (6.3-21.3) 3.4 (1.9-7.6) <0.001
Adiponectin/leptin ratio [mean (sd)] 1.00 (1.95) 2.29 (5.87) 0.02
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The adiponectin/leptin ratio was higher in patients with
no lipodystrophy and lower in patients with isolated cen-
tral fat accumulation, followed by the patients with mixed
forms of lipodystrophy (Table 3).
Sample characteristics, body composition, metabolic
parameters, adipokines and hormones related to body
composition, according to the presence lipodystrophy
defined by FMR
In this sample of 217 HIV-1 infected patients (144 men
and 73 women) on cART, 41% of patients presented lipo-
dystrophy defined by FMR (FMR-L). Table 4 shows the
characteristics of the study sample according to the
presence of FMR-L. Patients with FMR-L were morefrequently male, older and had a longer duration of HIV
infection and length of cART. No significant differences
were found in weight, BMI, waist, arm and thigh circum-
ferences among patients with or without FMR-L. Patients
with FMR-L had a higher neck circumference and waist/
hip ratio, but a lower hip circumference. Also, they had
significantly a higher mean CD4+ cell count, but no sig-
nificant difference in viral suppression rate was observed.
No differences were observed between patients with and
without FMR-L regarding cART regimens and CDC clas-
sification. Also, no differences were observed regarding
diastolic blood pressure, hs-CRP, total cholesterol, LDL
and HDL cholesterol levels. The patients with FMR-L had
higher systolic blood pressure, uric acid, triglycerides,
HOMA, fasting glucose and insulin levels. Regarding
Table 2 Body composition, adipokines and hormones related to body composition in HIV-infected patients, according
to gender
Male Female P
n 144 73
Age [years, mean (SD)] 46.8 (11.2) 46.2 (12.5) 0.72
BMI [(kg/m2), mean (SD)] 24.7 (3.8) 26.1 (5.6) 0.05
Waist circumference [cm, mean (SD)] 91.2 (10.6) 91.2 (13.5) 0.98
Hip circumference [cm, mean (SD)] 93.1 (6.7) 97.2 (10.5) 0.003
Total fat mass CT [cm3, mean (SD)] 243.4 (136.2) 356.0 (166.7) <0.001
VAT CT [cm3, mean (SD)] 140.7 (86.2) 113.6 (69.9) 0.02
SAT CT [cm3, mean (SD)] 102.6 (76.9) 242.4 (125.7) <0.001
VAT/SAT ratio 2.2 (2.4) 0.55 (0.40) <0.001
Total fat mass DXA [%, mean (SD)] 16.8 (8.1) 33.3 (10.0) <0.001
Trunk fat in DXA [%, mean (SD)] 20.6 (9.8) 33.4 (10.3) <0.001
Leg fat mass DXA [%, mean (SD)] 12.2 (9.1) 31.9 (12.5) <0.001
Arm fat mass DXA [%, mean (SD)] 15.2 (8.9) 42.3 (11.4) <0.001
Adiponectin [μg/mL, median (25th and 75th percentile)] 3.34 (1.79-6.59) 3.00 (1.36-6.55) 0.39
Leptin [ng/mL, median (25th and 75th percentile)] 3.0 (1.8-5.8) 11.2 (5.7-18.0) <0.001
Resistin [ng/mL, median (25th and 75th percentile)] 11.2 (8.4-17.0) 11.2 (8.9-16.8) 0.42
Ghrelin [pg/mL, median (25th and 75th percentile)] 55.5 (26.9-99.2) 44.0 (21.4-79.2) 0.07
PAI-1 [pg/mL, median (25th and 75th percentile)] 61.3 (38.5-104.3) 43.4 (30.8-95.8) 0.37
TNF-α [pg/mL, median (25th and 75th percentile)] 49.9 (31.6-72.4) 39.7 (27.2-60.0) 0.03
Adiponectin/leptin ratio, median (25th and 75th percentile) 0.945 (0.34-2.04) 0.245 (0.09-0.63) <0.001
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tients with FMR-L and as expected, QUICKI was lower in
patients with FMR-L.
On DXA evaluation, patients with FMR-L had lower
total, leg and arm fat mass (either in % or Kg) than pa-
tients without FMR-L with no significant difference inTable 3 Adipokines and hormones related to body compositi
No lipodystrophy
N = 23
Iso
acc
Age [years, mean (SD)] 39.9 (11.3)
BMI [kg/m2, mean (SD)] 23.0 (2.4)
Adiponectin [μg/mL, median (25th and
75th percentile)]
4.40 (2.43-8.75)
Leptin [ng/mL, median (25th and 75th percentile)] 3.0 (2.0-5.7)
Resistin [ng/mL, median (25th and
75th percentile)]
9.1 (7.9-12.6)
Ghrelin [pg/mL, median (25th and
75th percentile)]
72.0 (52.4-110.3) 7
PAI-1 [pg/mL, median (25th and 75th percentile)] 111.9 (64.8-162.8)
TNF-α [pg/mL, median (25th and 75th percentile)] 42.8 (33.1-60.5)
Adiponectin/leptin ratio median (25th and
75th percentile)
1.30 (0.97-2.50)trunk fat mass. On CT evaluation at abdominal level, pa-
tients with FMR-L had higher VAT and lower SAT with
a higher central/peripheral fat ratio, with no difference
in total fat at this level.
Leptin levels were lower in patients with FMR-L. No sig-
nificant differences were observed in levels of adiponectin,on according to four categories of body composition
lated central fat
umulation N = 56
Isolated
lipoatrophy N = 78
Mixed forms of
lipodystrophy N = 60
P
46.5 (12.6) 44.1 (9.7) 52.6 (10.8) <0.001
29.1 (4.4) 21.9 (2.8) 26.5 (3.2) <0.001
1.90 (0.89-3.48) 2.64 (1.20-6.53) 2.81 (1.04-5.22) 0.02
10.3 (5.3-15.1) 2.1 (1.4-3.3) 4.3 (2.4-7.0) <0.001
10.3 (7.2-12.0) 9.5 (8.1-15.3) 11.2 (8.1-16.4) 0.36
1.0 (41.3-110.8) 81.9 (46.2-194.3) 79.7 (52.4-122.4) 0.42
40.4 (30.6-45.8) 61.3 (28.3-96.4) 68.7 (34.6-109.6) 0.047
41.6 (27.7-83.4) 49.8 (30.7-72.6) 43.7 (29.6-79.8) 0.91
0.19 (0.06-0.38) 1.17 (0.43-4.60) 0.73 (0.20-1.43) <0.001
Table 4 Sample characteristic, body composition, adipokines and hormones related to body composition according to
the presence of lipodystrophy defined by FMR
Without lipodystrophy With lipodystrophy P
n (%) 128 (59.0) 89 (41.0) -
Gender [n (%)]
Male 76 (59.4) 68 (76.4)
Female 52 (40.6) 21 (23.6) 0.01
Age [years, mean (sd)] 44.7 (12.2) 49.4 (10.2) 0.003
Duration of HIV infection [years, mean (sd)] 7.4 (3.9) 8.6 (3.6) 0.007
cART [years, mean (sd)] 5.8 (3.8) 8.0 (3.4) <0.001
Weight [Kg, mean (sd)] 67.4 (13.0) 68.3 (11.1) 0.60
BMI [(kg/m2), mean (sd)] 25.0 (4.8) 25.3 (4.5) 0.68
Waist circumference [cm, mean (sd)] 90.2 (12.2) 92.7 (10.5) 0.10
Hip circumference [cm, mean (sd)] 95.9 (9.2) 92.5 (6.7) 0.002
Thigh circumference [cm, mean (sd)] 48.3 (5.6) 46.9 (4.8) 0.07
Arm circumference [cm, mean (sd)] 26.7 (3.2) 27.2 (2.7) 0.28
Neck circumference [cm, mean (sd)] 36.4 (3.8) 37.9 (3.7) 0.01
Waist/hip circumference ratio 0.94 (0.08) 1.00 (0.07) <0.001
CD4 cell count [cells/mm3, mean (sd)] 498.9 (289.4) 644.6 (354.1) 0.001
HIV RNA (<50) [n (%)] 109 (85.2) 81 (91.0) 0.45
HIV risk factor [n (%)]
Injecting drug user 36 (28.6) 17 (19.1)
Homosexual contact 7 (5.6) 16 (18.0)
Heterosexual contact 81 (64.3) 54 (60.7)
Others 2 (1.6) 2 (2.2) 0.02
CDC [n (%)]
A 67 (52.8) 57 (64.0) 0.16
B 2 (1.6) 0 (0)
C 58 (45.7) 32 (36.0)
ART [n (%)]
IP 65 (52.0) 48 (53.9) 0.89
NNRTI 62 (49.6) 45 (50.6) 0.89
NRTI 121 (96.8) 86 (96.6) 1.00
Total Cholesterol [mg/dL, mean (sd)] 218.1 (56.4) 233.1 (59.5) 0.06
LDL-cholesterol [mg/dL, mean (sd)] 125.4 (50.2) 133.0 (49.4) 0.27
HDL- cholesterol [mg/dL, mean (sd)] 47.2 (14.6) 44.4 (11.7) 0.14
Triglycerides [mg/dL, mean (sd)] 244.8 (117.6) 300.1 (195.3) 0.03
Uric acid [mg/L, mean (sd)] 43.8 (14.3) 51.0 (15.1) <0.001
Systolic blood pressure [mmHg, mean (sd)] 120.0 (18.6) 124.8 (15.6) 0.04
Diastolic blood pressure [mmHg, mean (sd)] 75.7 (11.8) 78.1 (10.5) 0.14
Glucose 0 [mg/dL, mean (sd)] 103.0 (39.5) 114.4 (43.7) 0.002
Glucose 2 h at OGTT [mg/dL, mean (sd)] 123.9 (42.9) 139.7 (49.0) 0.03
Insulin 0 [μU/mL, mean (sd)] 9,96 (10.50) 12.96 (10.55) 0.005
Insulin 2 h at OGTT [μU/mL, mean (sd)] 49. 8 (40.1) 88.3 (142.2) 0.005
HOMA [mean (sd)] 2.65 (3. 01) 3.70 (3.28) <0.001
QUICKI [mean (sd)] 0.37 (0.10) 0.34 (0.4) <0.001
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Table 4 Sample characteristic, body composition, adipokines and hormones related to body composition according to
the presence of lipodystrophy defined by FMR (Continued)
hsCRP [mg/dL, mean (sd)] 0.50 (0.90) 0.36 (0.27) 0.28
Adiponectin [μg/mL, mean (sd)] 5.64 (7.39) 3.95 (4.49) 0.23
Leptin [ng/mL, mean (sd)] 7.3 (8.5) 3.9 (3.3) 0.008
Resistin [ng/mL, mean (sd)] 12.8 (13.4) 12.8 (7.4) 0.37
Ghrelin[pg/mL, mean (sd)] 117.4 (133.6) 118.1 (106.7) 0.45
PAI-1 [pg/mL, mean (sd)] 62.6 (43.6) 102.1 (110.1) 0.26
TNF-α [pg/mL, mean (sd)] 61.9 (50.3) 52.3 (33.9) 0.43
Adiponectin/leptin ratio [mean (sd)] 2.72 (7.21) 1.69 (3.13) 0.42
Fat mass [%, mean (sd)] DXA
Total 24.8 (13.1) 19.3 (8.5) 0.002
Trunk 25.7 (13.3) 24.3 (9.0) 0.53
Leg 24.4 (14.7) 11.1 (7.4) <0.001
Arm 27.2 (17.1) 20.3 (13.6) 0.001
Fat mass [Kg, mean (sd)] DXA
Total 17.3 (11.1) 13.2 (7.3) 0.02
Trunk 9.3 (6.0) 9.0 (4.8) 0.69
Leg 5.2 (3.6) 2.1 (1.6) <0.001
Arm 2.1 (1.9) 1.5 (1.2) 0.008
Body Fat Mass by Quantitative CT
Total [cm2, mean (sd)] 282.9 (174.9) 276.5 (126.6) 0.92
VAT [cm2, mean (sd)] 111.2 (85.4) 139.4 (68.7) <0.001
SAT [cm2, mean (sd)] 171.7 (125.9) 117.0 (92.4) 0.001
VAT/SAT ratio [mean (sd)] 1.07 (1.46) 2.44 (2.60) <0.001
Note: cART – combined antiretroviral therapy; BMI. Body mass index; OGTT- oral glucose tolerance test; DXA - dual-energy X-ray absorptiometry CT – computed
tomography; VAT- visceral adipose tissue; SAT – subcutaneous adipose tissue.
Freitas et al. BMC Infectious Diseases 2014, 14:347 Page 7 of 13
http://www.biomedcentral.com/1471-2334/14/347resistin, ghrelin, PAI-1, TNF-α and adiponectin/leptin
ratio among patients with or without FMR-L (Table 4).
Adipokines, body composition hormones and metabolic
parameters
We evaluated the correlations between leptin, resistin,
TNF-α and adiponectin with age, waist/hip circum-
ference ratio, arm, waist, hip circumferences, BMI, fas-
ting glucose and insulin, HOMA, triglycerides and total
cholesterol in all the HIV-infected patients and HIV-
uninfected controls. Leptin was positively associated
with arm, waist, hip circumferences, BMI and fasting in-
sulin both in the HIV-infected patients and in HIV-
uninfected controls. In HIV-uninfected controls, leptin
was also positively correlated with HOMA. A negative
correlation was observed between resistin and hip cir-
cumference and BMI in the HIV-infected patients, while
a positive correlation between resistin and triglycerides
was found in the HIV-uninfected controls. Also, a nega-
tive correlation was observed between TNF-α and total
cholesterol in HIV-infected patients, and between adipo-
nectin and arm circumference in controls (Table 5).Regarding the effect of lipodystrophy on the asso-
ciation between anthropometric and metabolic para-
meters in HIV-infected patients, a significant positive
correlation was found between leptin and: insulin at
2 hours on OGTT; total, trunk, leg, arm fat evaluated by
DXA; and total, SAT, VAT/SAT ratio on abdominal level
evaluated by CT scan in these patients, regardless of the
presence of FMR-L. Leptin was also positively associated
with arm, thigh, waist, hip circumferences, BMI, glucose
at 2 hours on OGTT, total cholesterol, and was nega-
tively associated with length of cART in patients without
FMR-L. Patients with FMR-L also exhibited positive as-
sociations between resistin levels and duration of HIV-
infection, as well as between PAI-1 and VAT. A negative
association was found between adiponectin and arm fat
mass measured by DXA in FMR-L patients. A positive
correlation was observed between TNF-α, fasting glu-
cose and A1c in patients without FMR-L (Table 6).
The adiponectin/leptin ratio was not associated with
IR [HOMA (r = −0.148, p = 0.07) or QUICKI (r = 0.148,
p = 0.07)] in overall HIV patients and in male patients
[HOMA (r = −0.138, p = 0.16) or QUICKI (r = 0.126,
Table 5 Associations between adipokines and anthropometric and metabolic parameters in HIV patients and controls
Correlation
between
Leptin Resistin TNF-α Adiponectin
Total of HIV
patients
Controls Total of HIV
patients
Controls Total of HIV
patients
Controls Total of HIV
patients
Controls
n = 161 n = 67 n = 170 n = 74 n = 160 n = 74 n = 159 n = 74
r P R p r p r p R p r p r P r P
Age 0.05 0.55 −0.10 0.44 −0.02 0.84 −0.15 0.21 −0.007 0.92 −0.27 0.02 −0.05 0.52 −0.03 0.78
Wais/hip ratio 0.09 0.24 0.10 0.41 0.05 0.52 0.13 0.27 0.06 0.44 0.08 0.51 −0.09 0.23 −0.11 0.34
Waist circumference 0.43 <0.001* 0.36 0.003 −0.08 0.27 0.07 0.57 0.05 0.48 0.08 0.49 −0.1 0.19 −0.16 0.18
Hip circumference 0.41 <0.001* 0.54 <0.001* −0.15 0.04 0.03 0.78 0.005 0.95 0.1 0.41 −0.05 0.52 −0.11 0.36
Arm circumference 0.29 <0.001* 0.33 0.007 −0.11 0.21 −0.008 0.95 −0.05 0.47 0.04 0.72 −0.09 0.29 −0.24 0.04
BMI 0.51 <0.001* 0.49 <0.001* −0.17 0.02 0.01 0.92 0.05 0.52 0.12 0.32 −0.06 0.42 −0.18 0.13
Glucose at 0 −0.02 0.84 0.03 0.85 0.11 0.16 −0.04 0.74 0.10 0.17 −0.20 0.09 0.04 0.58 −0. 07 0.58
Insulin at 0 0.17 0.03 0.35 0.005 0.12 0.12 0.09 0.46 0.04 0.57 0.21 0.08 −0.12 0.11 0.02 0.87
HOMA 0.13 0.11 0.31 0.02 0.15 0.06 0.04 0.78 0.05 0.51 0.11 0.36 −0.11 0.15 0.01 0.92
Triglycerides −0.04 0.62 0.16 0.21 0.07 0.37 0.31 0.009 −0.13 0.09 −0.05 0.62 0.03 0.72 0.1 0.41
Total cholesterol 0.14 0.07 0.08 0.54 −0.01 0.87 0.1 0.42 −0.16 0.03 0.03 0.81 −0.03 0.71 0.04 0.14
*Significant p values after applying the Bonferroni correction.
Note: BMI. Body mass index.
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ratio and QUICKI was observed [HOMA (r = −0.228,
p = 0.10); QUICKI (r = 0.277, p = 0.04)] in females.
Discussion
In acquired or genetic lipodystrophies, abnormal fat dis-
tribution per se is a strong determinant of IR and meta-
bolic alterations, and the loss of fat likely precedes the
metabolic complications [21-24]. Increased amounts of
visceral fat accompanied by decrease in peripheral adi-
pose tissue are associated with an increase of lipolysis
and free fat acid fluxes, which together can alter adipo-
cytokine production [25].
Regarding body fat composition, our data showed that
there were differences in body fat distribution between
HIV-infected patients and HIV-uninfected controls, males
and females with HIV-infection and patients with or with-
out FMR-L despite similar BMI.
Actually, HIV-infected patients had less subcutaneous
adipose tissue, females had a higher fat mass and men
had higher VAT and VAT/SAT ratio. FMR-L patients
had less subcutaneous adipose tissue and more visceral
fat mass.
Leptin
Leptin levels were lower in HIV-infected patients namely
in those with FMR-L, pointing to an association with
body fat, demonstrated by the significant positive cor-
relation between leptin and body circumferences, BMI,
body fat mass evaluated by DXA and by CT scan. As
previously shown, we also observed that leptin concen-
trations were higher in HIV-infected women comparedto HIV-infected men and, therefore, the leptin sexual di-
morphism remains unchanged in HIV infection [26-28].
In genetic lipodystrophy syndromes, very low plasma
concentrations of leptin were observed when fat mass
was profoundly reduced [29] and that correlated posi-
tively with total adiposity [30].
In our sample, HIV-infected patients with isolated cen-
tral fat accumulation and mixed forms of lipodystrophy
had higher BMI and leptin levels. Leptin levels were
lower in those with isolated lipoatrophy, positively pro-
portional to BMI. Most studies, that did not differen-
tiated between patients with predominant lipoatrophy,
lipohypertrophy, and mixed patterns of fat redistribu-
tion, have failed to find significantly lower leptin levels
in subjects with HIV lipodystrophy [24,31,32], but when
subjects with distinctive lipoatrophy have been studied
separately, lower leptin levels in this subgroup of HIV
lipodystrophy patients has been observed. Also, signifi-
cant associations between leptin and subcutaneous fat
has been reported and decreased subcutaneous fat corre-
lated with reduced leptin levels after controlling for vis-
ceral fat quantity [33]. Total and regional adiposity were
strong and positively associated with leptin in healthy
controls and in HIV-infected patients, both in men and
women, suggesting that adiposity remains the major de-
terminant of plasma leptin levels in HIV infection [30].
In a prospective study, there was a significant positive
correlation between the appearance of lipoatrophy and
the leptin levels [32,34].
In our sample, leptin was positive and significantly as-
sociated with fasting and 2 hours insulin on OGTT and
HOMA in patients with FMR-L, and glucose and insulin
Table 6 Associations between adipokines and anthropometric and metabolic parameters in patients with and without
FMR defined lipodystrophy
Leptin Resistin PAI-1 TNF-α Adiponectin
Correlation between Without L With L Without L With L Without L With L Without L With L Without L With L
n = 96 n = 70 n = 96 n = 74 n = 28 n = 25 n = 101 n = 73 n = 99 n = 75
r r r r r r r r r r
Age 0.10 −0.01 −0.001 −0.10 −0.09 0.25 0.12 −0.19 0.04 −0.12
Duration of HIV-infection −0.06 0.38 −0.01 0.23 0.18 −0.11 0.11 0.11 0.13 0.16
Duration of cART −0.24 0.31 0.04 0.14 0.12 −0.16 0.05 0.05 0.04 0.21
Wais/hip ratio 0.12 0.15 0.05 0.02 0.10 0.14 0.15 −0.01 0.06 −0.19
Thigh circumf. 0.48* −0.02 −0.17 −0.12 −0.004 0.06 −0.06 −0.02 0.07 0.07
Cervical circumf. −0.06 −0.24 −0.02 −0.18 0.17 0.11 0.21 −0.03 −0.08 −0.08
Waist circumf. 0.53* 0.20 −0.11 0.03 −0.06 0.18 0.08 −0.01 −0.19 −0.19
Hip circumf. 0.65* 0.15 −0.20 −0.03 −0.07 0.06 −0.04 −0.04 −0.04 −0.04
Arm circumf. 0.47* −0.06 −0.02 −0.21 −0.13 0.12 0.01 −0.21 −0.07 −0.07
CD4 cell count −0.09 0.02 −0.01 −0.11 0.29 0.21 0.03 0.02 −0.09 −0.12
BMI 0.66* 0.17 −0.19 −0.09 −0.007 0.04 0.08 −0.02 −0.03 −0.13
Glucose at 0 0.07 −0.03 0.15 0.01 0.08 0.09 0.22 0.002 0.12 0.02
Glucose at 2 h on OGTT 0.25 0.12 0.12 0.12 −0.20 −0.12 0.06 −0.02 −0.02 −0.06
Insulin at 0 0.17 0.31 0.05 0.22 −0.10 0.03 0.09 0.12 −0.08 −0.12
Insulin at 2 h on OGTT 0.36 0.39 0.06 0.17 −0.21 −0.32 0.11 0.19 −0.08 −0.14
HOMA 0.18 0.27 0.08 0.25 −0.03 0.03 0.11 0.11 −0.06 −0.11
A1c 0.15 0.008 0.19 0.11 −0.34 −0.02 0.24 0.00 0.14 −0.02
Triglycerides −0.004 0.03 0.06 0.17 −0.17 −0.18 −0.13 −0.17 0.08 −0.03
Total cholesterol 0.25 −0.01 −0.01 −0.06 −0.29 0.09 0.18 −0.17 −0.13 0.09
Total fat mass DXA % 0.877* 0.561* −0.14 0.07 −0.05 −0.05 −0.07 −0.12 −0.17 −0.19
Trunk fat mass DXA % 0.858* 0.547* −0.14 0.07 −0.05 0.001 −0.02 −0.10 −0.15 −0.20
Leg fat mass DXA % 0.825* 0.464* −0.15 0.02 −0.06 −0.07 −0.09 −0.13 −0.15 −0.19
Arm fat mass DXA % 0.857* 0.650* −0.12 0.08 −0.08 −0.19 −0.09 −0.10 −0.21 −0.06
Total fat mass in CT 0.774* 0.515* −0.19 0.15 −0.07 0.07 0.13 −0.04 −0.08 −0.14
VAT in CT 0.483* 0.119 −0.18 0.14 0.05 0.41 0.05 −0.04 −0.07 −0.19
SAT in CT 0.829* 0.587* −0.18 0.12 −0.10 −0.01 0.08 −0.06 −0.09 −0.03
_ −0.421* −0.475* 0.10 −0.04 0.04 0.31 0.002 0.07 0.003 0.004
*p values <0.001 (significant applying the Bonferroni corretion).
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role of leptin in the modulation of insulin sensitivity is
complex. Extremely low levels of leptin in congenital
generalized lipoatrophies were associated with severe IR,
and significantly improved with replacement of leptin in
mice and humans [35]. In conclusion, leptin levels
appear to be primarily determined by total adiposity in
HIV-infected individuals, independently of the presence
of lipodystrophy [30].
Adiponectin
In our sample, adiponectin levels were higher in controls
than in HIV-infected patients. Patients with no lipody-
strophy had higher levels of adiponectin and patientswith isolated central fat accumulation had the lowest
levels of adiponectin. Contrary to other authors, who
found higher adiponectin levels in HIV-infected women
[26,27], no such gender difference was observed in our
patients, and no difference regarding the presence of
FMR-L was also found. We found a significant negative
correlation between adiponectin and total and trunk fat
mass evaluated by DXA in the HIV-infected patients,
and with arm fat mass in patients without FMR-L.
Kosmiski et al., observed that both total and regional
adiposity were significant and negatively correlated with
adiponectin levels in a control group, similar to other
reports of general populations [30]. Also, these HIV-
infected patients with leg SAT below the 10th percentile
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controls with similar leg SAT volumes [30]. In some stu-
dies, no association between adiponectin and total adipos-
ity was found in HIV-infected patients, while adiponectin
was positively correlated with both extremity and ab-
dominal SAT [36,37]. These relationships suggest that the
remaining SAT in HIV-infected patients with moderate to
severe lipoatrophy is dysfunctional rather than simply
reduced in size, as for example, patients suffering from
anorexia nervosa, a condition characterized by low body
weight and severe global fat depletion (although not iso-
lated subcutaneous adipose tissue), adiponectin levels are
higher [38-40]. Findings of abnormal function or loss of
adipose tissue in partial lipodystrophy syndromes (due to
lamin A/C or to PPAR-γ receptor mutations) and low adi-
ponectinemia also support the hypothesis that low adipo-
nectin concentrations in HIV-infected subjects with low
levels of SATare due to lipodystrophy per se [39,40]. Thus,
lipodystrophies are characterized not only by a fat de-
creased but also by dysfunction or loss of adipocytes [30].
In HIV-infected men and women, with or without lipody-
strophy, the normal negative relationship between visceral
adiposity and adiponectin was maintained [30,36,37,41].
In HIV-infected patients, adiponectin levels correlated
significantly with the percentage of limbs fat and insulin
sensitivity [24,42], although some authors state that adi-
ponectin predicts insulin sensitivity independently of the
amount and repartition of body fat [28], no such asso-
ciation was found between adiponectin and markers of
IR in our sample.
It has been reported that in HIV lipodystrophic pa-
tients, adiponectin levels were significantly lower in pa-
tients with fat redistribution (and correlated inversely
with serum triglycerides). The lowest levels were in per-
ipheral lipoatrophic and central lipohypertrophic pa-
tients playing a central role in glucose, lipid metabolism
and IR in these patients [28,37,43,44].
Ratio adiponectin/leptin
Adiponectin/leptin ratio is considered to be a better pre-
dictor of insulin sensitivity and cardiovascular risk, and
is usually considered independent of body mass. Adipo-
nectin/leptin ratio has been negatively associated with
IR, metabolic defects and cardiovascular risk markers
[28]. We also found a positive correlation between this
ratio and QUICKI index in women. This ratio was
higher in patients with no lipodystrophy and lower in
patients with isolated central fat accumulation, followed
by the patients with mixed forms of lipodystrophy.
Resistin
Elevated resistin levels have been observed in obese and
diabetic subjects, and increased resistin has been asso-
ciated with IR in lean and obese subjects [45]. However,other studies found no association between circulating
resistin levels and IR [46,47].
In our data, resistin was higher in controls and no sig-
nificant differences were found in the four categories of
body composition, or according to gender and presence of
FMR-L in HIV-infected patients, similar to previously pub-
lished data [48]. However, others found that resistin plasma
levels were higher in lipodystrophic patients, being highest
in those with isolated lipoatrophy [49]. Resistin was posi-
tively associated with duration of HIV-infection and with
HOMA in patients with FMR-L, and negatively with hip
circumference. Some authors previously demonstrated a
correlation between resistin plasma levels and insulin re-
sistance in lipodystrophic HIV patients [50] and others in
HIV patients either with or without lipodystrophy [49].
TNF- α
HIV lipodystrophy, familial partial lipodystrophy and
obesity have been associated with high circulating levels
of TNF-α [39,51,52]. In our sample, no significant diffe-
rences in TNF-α levels were observed between controls
and HIV-infected patients, in patients with or without
FMR-L or regarding the four categories of fat compo-
sition. However, we found a positive correlation between
TNF-α and fasting glucose and A1c in patients without
FMR-L.
TNF-α homeostasis is profoundly altered by HIV-1
infection itself [53] and it has been shown that HIV-1
infected patients have elevated pre-treatment levels of
TNF-α but these levels dramatically decrease when cART
is initiated [54]. In our sample, patients have been treated
for a long period of time (maximum 20 years) and this
could potentially explain similar levels in controls and
HIV-infected patients. However, other authors showed
that concentrations of the components of TNF-α system
are not normalized when cART is effective. We did not
observe any correlation between TNF-α and adiponectin
levels (r = 0.145; p = 0.06) although that has previously
been described [54].
PAI-1
Patients with no lipodystrophy and mixed forms of lipo-
dystrophy had higher levels of PAI-1, placing them at
substantial risk of cardiovascular disease via impaired
fibrinolysis (54). In our sample, the lowest levels of PAI-
1 were found in those with isolated central fat accumu-
lation. No differences in PAI-1 levels between patients
with or without FMR-L and according to gender were
found, but a significant positive association between
PAI-1 and VAT was observed in patients with FMR-L.
PAI-1 concentrations are increased in conditions cha-
racterized by increased VAT or SAT, hypertriglyceridemia,
and hyperinsulinemia. Both VAT and SAT produce PAI-1,
but data are controversial as to whether VAT produces
Freitas et al. BMC Infectious Diseases 2014, 14:347 Page 11 of 13
http://www.biomedcentral.com/1471-2334/14/347more, similar, or less amounts of PAI-1 than SAT. Also, it
has been suggested that PAI-1 originates from stromal
cells in adipose tissue rather than from adipocytes. Pa-
tients with cART-associated lipodystrophy had elevated
plasma PAI-1 concentrations [55]. HIV infected patients
with fat redistribution had significant elevations in PAI-1,
being waist–to-hip ratio the only significant predictor of
PAI-1 [56].
Contrary to our data, He et al., found significantly
increased plasma levels of PAI-1 in patients with lipody-
strophy. They also found a positive correlation between
plasma PAI-1 level and BMI, waist circumference, VAT,
plus an inverse correlation with the percentage of limb fat.
In a stepwise multiple linear regression model, VAT
turned out to be the main predictor of plasma PAI-1 [57].
Ghrelin
Ghrelin was higher in HIV-infected patients than in con-
trols. Fasting levels of serum ghrelin has been negatively
correlated with BMI, and it is decreased in obesity and in-
creased in cachexia [58]. Contrary to our data, lower levels
of ghrelin have been reported in HIV-infected lipody-
strophic patients [5,59]. Falasca et al., observed higher
levels of ghrelin in patients with hypertriglyceridemia, as
well as a positive correlation between ghrelin and trigly-
ceride levels in patients with hypertriglyceridemia. No
such association between ghrelin and triglyceride levels
were observed in our sample (r = 0.064, p = 0.42). Falasca
concluded that adipokines may have crucial roles in the
pathogenesis of hypertriglyceridemia and, thus, moni-
toring of ghrelin levels could be important to identify sub-
jects with high cardiovascular risk [58].
Limitations
Several limitations of this study should be noted. A cross-
sectional design impairs establishing causality between
cART use, lipoatrophy, and alterations in adipokine levels.
It is not possible to determine whether adipokine abnor-
malities are due to reduced hormone expression in adi-
pose tissue, decreased differentiation or decreased adipose
cell numbers. The body fat redistribution was assessed
clinically and patients divided in 4 groups but this does
not preclude that some patients categorized into one sub-
set could in fact have minor subclinical changes in their
fat distribution not detectable by physical examination.
Some aspects of the current study should be highlighted
The study was performed in a highly experienced unit in
the assessment of metabolic and body fat abnormalities
in HIV-infected patients; the clinical assessment of lipo-
dystrophy was performed by the same investigator (PF);
and objective definitions of lipodystrophy (Fat Mass
Ratio by DXA), visceral and subcutaneous fat mass by
CT were used.Conclusion
Leptin levels were lower in patients with lipodystrophy,
indicating its close relationship with total body fat.
A significant positive correlation between leptin and
HOMA in patients with lipodystrophy demonstrated the
role of this adipokine in insulin resistance. Adiponectin
was lower in patients with isolated central fat accumu-
lation and negatively correlated with visceral adipose tis-
sue. The adiponectin/leptin ratio was lower in patients
with isolated central fat accumulation. Patients with
mixed forms of lipodystrophy had higher levels of PAI-1.
Resistin was positively associated with HOMA in pa-
tients with FMR-defined lipodystrophy. Patients with no
lipodystrophy and mixed forms of lipodystrophy had
higher levels of PAI-1 and the lowest levels of PAI-1
were found in those with isolated central fat accumula-
tion. Ghrelin was higher in HIV-infected patients than
in controls despite the two groups being BMI-matched.
Our results add to the evidence on the complexity of the
relationship between adipokines, hormones related to
body composition, and insulin resistance in the HIV re-
distribution syndrome, with different degrees of peri-
pheral fat atrophy and central fat accumulation.
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